Sugi Predict

Sugi Predict / Compounds / SCHEMBL1306056

SCHEMBL1306056

SCHEMBL1306056

COCCN1CCN(c2ccc(C(=O)O)cc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ HTR1A P08908 1/20 0.52
▸ USP2 O75604 1/20 0.51
▸ SOD1 P00441 1/20 0.50
▸ DRD2 P14416 2/20 0.49
▸ HTR2A P28223 1/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ MAPT P10636 1/20 0.48
▸ POLB P06746 3/20 0.48
▸ CHEK1 O14757 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.47
▸ DRD4 P21917 2/20 0.46
▸ HRH3 Q9Y5N1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5787020 0.99 MEN1 (0.54) MEN1KMT2AHTR1AUSP2SOD1
SCHEMBL14103827 0.88 KMT2A (0.58) MEN1KMT2AHTR1ASOD1KDM4E
SCHEMBL7067533 0.87 MEN1 (0.54) MEN1KMT2AHTR1ASOD1DRD2
SCHEMBL5787289 0.87 MAPT (0.59) MEN1KMT2AHTR1ASOD1KDM4E
SCHEMBL6134389 0.86 DRD3 (0.51) MEN1KMT2ADRD2HTR2ACHEK1
SCHEMBL1305865 0.83 DRD2 (0.65) MEN1KMT2AHTR1AUSP2SOD1
Hydrochloric Acid SCHEMBL1841012 0.82 DRD2 (0.63) MEN1KMT2AHTR1AUSP2SOD1
SCHEMBL10900979 0.82 DRD2 (0.63) MEN1KMT2AHTR1ADRD2HTR2A
SCHEMBL63379 0.81 KDM4E (0.54) MEN1KMT2AHTR1AUSP2DRD2
SCHEMBL4238787 0.81 KDM4E (0.56) MEN1KMT2AHTR1AUSP2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877927-B2 Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl proteinase inhibitors GRUNENTHAL GMBH (DE) 2014-11-04 — — US disclosed
CN-101511841-B Tetrahydrofuro [3,2-B ] pyrrol-3-ones as cathepsin K inhibitors AMURA THERAPEUTICS LTD 2013-08-07 — — CN disclosed
EP-2044075-B1 FURO [3, 2-B] PYRROL DERIVATIVES AMURA THERAPEUTICS LTD (GB) 2013-01-02 — — EP disclosed
EP-2046796-B1 TETRAHYDROFURO [3, 2 -B]PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS AMURA THERAPEUTICS LTD (GB) 2012-10-24 — — EP disclosed
EP-2046795-B1 FURO[3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS AMURA THERAPEUTICS LTD (GB) 2012-10-17 — — EP disclosed
EP-2046797-B1 FURO [3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS AMURA THERAPEUTICS LTD (GB) 2012-05-23 — — EP disclosed
EP-2046798-B1 FURO [3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS AMURA THERAPEUTICS LTD (GB) 2012-05-16 — — EP disclosed
US-8053437-B2 Furo[3. 2-B] pyrrol derivatives AMURA THERAPEUTICS LIMITED (GB) 2011-11-08 — — US disclosed
US-7846934-B2 Furo[3,2-B] pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors AMURA THERAPEUTICS LIMITED (GB) 2010-12-07 — — US disclosed
US-7846935-B2 Furo[3,2-B]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors AMURA THERAPEUTICS LIMITED (GB) 2010-12-07 — — US disclosed
EP-2046795-A1 FURO[3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS Amura Therapeutics Limited (GB) 2009-04-15 — — EP disclosed
EP-2046797-A1 FURO [3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS Amura Therapeutics Limited (GB) 2009-04-15 — — EP disclosed
EP-2044075-A1 FURO [3, 2-B] PYRROL DERIVATIVES Amura Therapeutics Limited (GB) 2009-04-08 — — EP disclosed
WO-2008007127-A1 FURO [3,2-B] PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS AMURA THERAPEUTICS LIMITED (GB) 2008-01-17 — — WO disclosed
WO-2008007114-A1 TETRAHYDROFURO [3, 2 -B] PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS AMURA THERAPEUTICS LIMITED (GB) 2008-01-17 — — WO disclosed
WO-2008007109-A1 FURO[3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS AMURA THERAPEUTICS LIMITED (GB) 2008-01-17 — — WO disclosed
WO-2008007103-A1 FURO [3, 2-B] PYRROL DERIVATIVES AMURA THERAPEUTICS LIMITED (GB) 2008-01-17 — — WO disclosed
WO-2008007130-A1 FURO [3,2-B] PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS AMURA THERAPEUTICS LIMITED (GB) 2008-01-17 — — WO disclosed
WO-2008007112-A1 TETRAHYDROFURO [3, 2-B] PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS AMURA THERAPEUTICS LIMITED (GB) 2008-01-17 — — WO disclosed
US-20040249153-A1 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases NOVARTIS AG (CH) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040249153-A1 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases CTSK, CTSS, CTSZ MEN1 4491/4885KMT2A 2879/4885HTR1A 3815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.